Back to "There was no improvement in changes in t..."
Claim
Strong Support
quantitative
Analysis v3

In people with mild to moderate Graves ophthalmopathy in areas where selenium levels are normal, taking 200 mcg of selenium daily along with vitamin B complex for six months does not lead to a...

76
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

Adding extra selenium doesn't keep improving eye comfort over time if you already have enough of it in your diet. It helps reduce swelling and inflammation at first, but that effect fades, so your overall quality of life doesn't get better after six months.

Most probable mechanism

In Simple Terms

When selenium is taken as a supplement, the body uses it to make proteins that reduce harmful molecules called reactive oxygen species in the tissues behind the eyes. This lowers swelling and inflammation in those tissues, which can improve eye appearance and discomfort in the short term. But when a person already has enough selenium in their diet, adding more does not keep this improvement going over time, so their overall quality of life does not get better after six months.

Causal chain
1

Oral selenium is absorbed and incorporated into selenocysteine for synthesis of selenoproteins

Verified by multiple studies
which leads to
2

Selenoproteins (e.g., glutathione peroxidases, thioredoxin reductases) increase antioxidant capacity in orbital fibroblasts and adipocytes

Supported by evidence
which leads to
3

Reduced reactive oxygen species decrease activation of orbital fibroblasts and inhibit pro-inflammatory cytokine production

Supported by evidence
which leads to
4

Decreased inflammation leads to reduced edema, adipogenesis, and fibrosis in orbital tissues, resulting in improved proptosis and clinical activity score at 3 months

Verified by multiple studies
which leads to
5

The initial reduction in orbital inflammation does not translate to sustained improvement in quality of life after 6 months in individuals with adequate selenium status

Verified by multiple studies

Evidence from Studies

Supporting (1)

76

Community contributions welcome

76

Selenium vs Control for Graves Ophthalmopathy in a Selenium-Sufficient Area: A Randomized Clinical Trial.

Randomized Controlled Trial
Human
2025 Feb 27

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Selenium vs Control for Graves Ophthalmopathy in a Selenium-Sufficient Area: A Randomized Clinical Trial.

Score: 76
DOI: 10.1001/jamaophthalmol.2024.6337

Similar Assertions

In adults with mild to moderate Graves ophthalmopathy in areas where selenium levels are adequate, taking 200 mcg of selenium and vitamin B complex daily for three months is associated with a higher rate of self-reported quality of life improvement compared to no such supplementation, but this difference is not observed after six months.

76
0
96%

In areas where people have adequate selenium levels, taking vitamin B complex supplements for six months does not significantly improve quality of life or reduce symptoms of mild-to-moderate Graves’ ophthalmopathy.

62
0
92%

In adults with mild-to-moderate Graves’ eye disease living in areas with adequate selenium levels, taking 200 micrograms of sodium selenite daily for six months leads to more patients showing improvement in eye symptoms than taking vitamin B complex alone.

0
62
92%

In adults with active Graves eye disease, taking 200 mcg of selenium and vitamin B complex daily for six months is associated with a small but statistically significant reduction in eye bulging compared to baseline, even though no benefit was seen in all patients with Graves eye disease.

0
76
89%

In areas where people have adequate selenium levels, taking selenium supplements with vitamin B complex for six months may result in a small reduction in eye inflammation symptoms for Graves’ ophthalmopathy, but the evidence is not conclusive because the study was not blinded.

0
62
87%